饮酒与代谢综合征的双向影响:进行性脂肪性肝病的协同因素
本文综述饮酒与代谢综合征组分如何协同或超叠加地驱动脂肪性肝病的发生与进展,并讨论临床应对策略。当前实践将脂肪性肝病人为分为酒精性肝病与非酒精性脂肪性肝病,而两者常共存并相互增敏。
要点
- 饮酒与代谢综合征组分共存时对肝损伤呈协同或超叠加效应。
- 二者相互增敏,共同驱动并可能加速脂肪性肝病的发生。
- 临床需关注饮酒与代谢因素的交互作用而非孤立分类。
核心结论
- 饮酒与代谢综合征组分相互作用,对脂肪性肝病的发生和进展产生协同或超叠加效应。
研究设计与样本
- 综述,检索并汇总流行病学证据与科学文献,探讨饮酒与代谢综合征组分的交互作用。
主要发现
- 当前医学实践将脂肪性肝病人为二分为酒精性肝病与非酒精性脂肪性肝病。
- 普通人群中肥胖与代谢综合征患病率急剧增加,这些因素与饮酒在相当比例人群中并存。
- 每种暴露均使肝脏对另一种暴露的损伤效应增敏,该交互作用驱动并可能加速肝病的发生。
临床怎么用
- 作者讨论了如何在临床实践中应对饮酒与代谢综合征组分之间的交互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current medical practice artificially dichotomises a diagnosis of fatty liver disease into one of two common forms: alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD). Together, these account for the majority of chronic liver diseases worldwide. In recent years, there has been a dramatic increase in the prevalence of obesity and metabolic syndrome within the general population. These factors now coexist with alcohol consumption in a substantial proportion of the population. Each exposure sensitises the liver to the injurious effects of the other; an interaction that drives and potentially accelerates the genesis of liver disease. We review the epidemiological evidence and scientific literature that considers how alcohol consumption interacts with components of the metabolic syndrome to exert synergistic or supra-additive effects on the development and progression of liver disease, before discussing how these interactions may be addressed in clinical practice.
引用
- Boyle M, Masson S, Anstee QM, et al. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol. 2017. PMID: 29113910. doi:10.1016/j.jhep.2017.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。